BRPI0911874A2 - composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato - Google Patents

composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato

Info

Publication number: BRPI0911874A2
Authority: BR; Brazil
Prior art keywords: acamprosate; zonisamide; alzheimer; disease; treatment
Prior art date: 2008-04-29

Application number

BRPI0911874-8A

Other languages

English (en)

Inventor

Cohen Daniel

Chumakov Ilya

Nabirochkin Serguei

Guerassimenko Oxana

Cholet Nathalie

Original Assignee

Pharnext

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-29

Filing date

2009-04-29

Publication date

2018-05-22

2009-04-29 Application filed by Pharnext filed Critical Pharnext

2018-05-22 Publication of BRPI0911874A2 publication Critical patent/BRPI0911874A2/pt

Links

208000024827 Alzheimer disease Diseases 0.000 title 1
AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
229960004047 acamprosate Drugs 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 title 1
229960002911 zonisamide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0911874-8A 2008-04-29 2009-04-29 composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato BRPI0911874A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4858208P	2008-04-29	2008-04-29
US61/048,582		2008-04-29
PCT/EP2009/055176 WO2009133128A1 (en)	2008-04-29	2009-04-29	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Publications (1)

Publication Number	Publication Date
BRPI0911874A2 true BRPI0911874A2 (pt)	2018-05-22

Family

ID=40848096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911874-8A BRPI0911874A2 (pt)	2008-04-29	2009-04-29	composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato

Country Status (15)

Country	Link
US (3)	US20110269764A1 (pt)
EP (2)	EP3560496A1 (pt)
JP (2)	JP5933258B2 (pt)
KR (1)	KR20110071050A (pt)
CN (2)	CN102065858B (pt)
AU (1)	AU2009242113B2 (pt)
BR (1)	BRPI0911874A2 (pt)
CA (1)	CA2722295C (pt)
EA (1)	EA024147B1 (pt)
ES (1)	ES2764480T3 (pt)
IL (2)	IL208981B (pt)
MX (1)	MX2010011878A (pt)
NZ (1)	NZ589304A (pt)
WO (1)	WO2009133128A1 (pt)
ZA (1)	ZA201008038B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
ES2332687B1 (es) *	2008-03-13	2011-01-10	Proyecto De Biomedicina Cima, S.L.	Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
WO2009133128A1 (en) *	2008-04-29	2009-11-05	Pharnext	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en)	2008-06-18	2009-12-23	Pharnext	Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
HUE026815T2 (en)	2008-11-19	2016-07-28	Forum Pharmaceuticals Inc	Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US9925282B2 (en)	2009-01-29	2018-03-27	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
AU2010247835A1 (en) *	2009-05-11	2011-12-08	Envivo Pharmaceuticals, Inc.	Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US9387206B2 (en)	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) *	2009-11-03	2011-05-18	Pharnext	New therapeutics approaches for treating alzheimer disease
TWI519532B (zh)	2010-05-17	2016-02-01	艾維沃製藥公司	（Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US9320793B2 (en) *	2010-07-14	2016-04-26	Acumen Pharmaceuticals, Inc.	Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
DE102010062810B4 (de) *	2010-09-07	2014-03-13	Immungenetics Ag	2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
US9241933B2 (en)	2011-03-01	2016-01-26	Pharnext	Compositions for treating amyotrophic lateral sclerosis
US9248111B2 (en) *	2011-03-01	2016-02-02	Pharnext	Therapeutic approaches for treating parkinson's disease
US10010515B2 (en)	2011-03-01	2018-07-03	Pharnext	Therapeutic approaches for treating Parkinson's disease
EP2705842A1 (en) *	2012-09-05	2014-03-12	Pharnext	Therapeutic approaches for treating parkinson's disease
US9867837B2 (en)	2011-03-01	2018-01-16	Pharnext	Compositions for treating neurological disorders
RS53227B (sr)	2011-03-01	2014-08-29	Pharnext	Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
UA115968C2 (uk)	2011-03-01	2018-01-25	Фарнекст	Нові композиції для лікування неврологічних захворювань
JP6430445B2 (ja) *	2011-03-01	2018-11-28	ファーネクストＰｈａｒｎｅｘｔ	バクロフェンおよびアカンプロセートに基づく神経疾患の治療
US9931326B2 (en)	2011-03-29	2018-04-03	Pharnext	Composition comprising torasemide and baclofen for treating neurological disorders
EP2535049A1 (en)	2011-06-17	2012-12-19	Proyecto de Biomedicina Cima, S.L.	Tadalafil for the treatment of dementia
SI2819664T1 (sl) *	2012-03-01	2017-12-29	Pharnext	Novi sestavki za zdravljenje amiotrofične lateralne skleroze
AU2013224959B2 (en) *	2012-03-01	2017-12-07	Pharnext	New compositions for treating amyotrophic lateral sclerosis
RU2017136693A (ru)	2012-05-08	2019-02-08	Форум Фармасьютикалз, Инк.	Способы поддержания, лечения или улучшения когнитивной функции
EP2705841A1 (en) *	2012-09-05	2014-03-12	Pharnext	Combinations of nootropic agents for treating cognitive dysfunctions
US10058530B2 (en)	2012-10-25	2018-08-28	The General Hospital Corporation	Combination therapies for the treatment of Alzheimer's disease and related disorders
CN104869993B (zh)	2012-10-25	2019-01-15	通用医疗公司	治疗阿尔茨海默病及相关疾病的组合疗法
US10626163B2 (en)	2013-01-25	2020-04-21	Brandeis University	Methods of modulating GABAergic inhibitory synapse formation and function
CN103040800A (zh) *	2013-01-28	2013-04-17	杭州雷索药业有限公司	吉非罗齐在制备抗血管生成类药物中的应用
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
US10525005B2 (en)	2013-05-23	2020-01-07	The General Hospital Corporation	Cromolyn compositions and methods thereof
AU2014340182B2 (en)	2013-10-22	2019-05-23	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
EP3104850A1 (en)	2014-02-11	2016-12-21	Pharnext	Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
EP4218771A1 (en) *	2015-03-27	2023-08-02	Yeda Research and Development Co. Ltd	Methods of treating motor neuron diseases
EP3364993B1 (en)	2015-10-22	2022-11-09	Cavion, Inc.	Methods for treating angelman syndrome
CN109715194B (zh)	2016-08-03	2024-06-11	南佛罗里达大学	用于治疗神经障碍的颤蛋白组合物
US20190240194A1 (en)	2016-08-31	2019-08-08	The General Hospital Corporation	Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US10736876B2 (en)	2017-04-24	2020-08-11	Pharnext	Idalopirdine-based combinatorial therapies of Alzheimer's disease
EP3615521A4 (en) *	2017-04-26	2021-02-17	Cavion, Inc.	METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
CA3099090A1 (en) *	2017-05-26	2018-11-29	Chase Therapeutics Corporation	Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
WO2019009985A1 (en) *	2017-07-05	2019-01-10	Goetzl Edward J	BIOMARKERS OF EXCITATORIC SYNAPTIC PROTEINS SPECIALIZED WITH PLASMA NEURAL EXOSOMES FOR THE PREDICTION AND STADIFICATION OF ALZHEIMER'S DISEASE
CN111565711B (zh)	2017-07-20	2023-01-03	阿茨治疗股份有限公司	色甘酸钠和布洛芬的粉末化制剂
WO2019038584A1 (en)	2017-08-19	2019-02-28	Ftf Pharma Private Limited	An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US11439608B2 (en)	2017-09-25	2022-09-13	Qun Lu	Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
KR20210071943A (ko)	2018-07-02	2021-06-16	더 제너럴 하스피탈 코포레이션	크로몰린 소듐 및 α-락토스의 분말화된 제형
JP7480131B2 (ja)	2018-10-03	2024-05-09	カビオン・インコーポレイテッド	（ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
US12383528B2 (en)	2018-12-10	2025-08-12	The General Hospital Corporation	Cromolyn esters and uses thereof
CN109402124A (zh) *	2018-12-11	2019-03-01	宁夏医科大学总医院	一种环状RNA hsa-circ-0006969及其特异性扩增引物和应用
WO2021207060A1 (en)	2020-04-06	2021-10-14	The General Hospital Corporation	Methods of treatment of coronavirus-induced inflammation conditions
EP4151213A4 (en) *	2020-05-11	2024-05-29	Shimadzu Corporation	THERAPEUTIC FOR MILD COGNITIVE IMPAIRMENT
US12612391B2 (en)	2020-12-28	2026-04-28	The General Hospital Corporation	Cromolyn derivatives and uses thereof
CA3230151A1 (en)	2021-08-31	2023-03-09	Cerespir Incorporated	Co-crystals

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727278B1 (en) *	1986-08-27	2004-04-27	Dms Pharmaceutical Inc.	Pharmaceutically active agents that impede amyloid formation in vivo
JP2654688B2 (ja) *	1989-05-17	1997-09-17	東燃株式会社	オレフィン重合用触媒成分
IL117149A0 (en) *	1995-02-23	1996-06-18	Schering Corp	Muscarinic antagonists
DE69833000T2 (de) *	1997-09-26	2006-09-07	Noven Pharmaceuticals, Inc., Miami	Bio-klebemittelzusammensetzungen
ES2244103T3 (es) *	1997-12-26	2005-12-01	Dainippon Pharmaceutical Co., Ltd.	Remedio para enfermedades neurodegenerativas.
US20070004670A1 (en) *	1998-07-31	2007-01-04	Richard Wurtman	Compositions containing citicoline, and methods of use thereof
AU1238500A (en) *	1998-11-02	2000-05-22	Alza Corporation	Controlled delivery of active agents
WO2000076478A1 (en) *	1999-06-14	2000-12-21	Cosmo S.P.A.	Controlled release and taste masking oral pharmaceutical compositions
CA2403442A1 (en) *	2000-03-17	2002-09-17	Ajinomoto Co., Inc.	Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications
JP2003113120A (ja) *	2001-08-03	2003-04-18	Takeda Chem Ind Ltd	徐放性医薬
US7407986B2 (en) *	2001-12-18	2008-08-05	Brassica Foundation For Chemoprotection Research, Inc.	Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
US20040102525A1 (en) *	2002-05-22	2004-05-27	Kozachuk Walter E.	Compositions and methods of treating neurological disease and providing neuroprotection
JP2005535665A (ja) *	2002-07-09	2005-11-24	ザスクリプスリサーチインスティテュート	虚血および再灌流損傷を防止する方法
US20080050315A1 (en) *	2004-03-24	2008-02-28	Stefan Golz	Diagnostics and Therapeutics for Diseases Associated with Protein Kinase, Cgmp-Dependent, Type I (Prkg1)
JP2006143708A (ja) *	2004-10-19	2006-06-08	Ono Pharmaceut Co Ltd	神経変性疾患治療用医薬
WO2006078948A2 (en) *	2005-01-21	2006-07-27	Teva Pharmaceutical Industries Ltd.	Stable pharmaceutical formulations of zonisamide and methods for their manufacture
US20090298864A1 (en) *	2005-04-11	2009-12-03	The Trustees Of Columbia University In The City Of New York	Methods for Treating Mild Cognitive Impairment
US20080188510A1 (en) *	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
EP1928445A1 (en) *	2005-09-16	2008-06-11	Cereuscience AB	Method and means of preventing and treating sleep disordered breathing
PL1954241T3 (pl) *	2005-11-28	2013-03-29	Orexigen Therapeutics Inc	Formulacja zonisamidu o przedłużonym uwalnianiu
WO2008010768A1 (en) *	2006-07-17	2008-01-24	Cereuscience Ab	Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
WO2008141074A1 (en) *	2007-05-10	2008-11-20	Salk Institute For Biological Studies	Identification of compounds that protect against amyloid diseases
NZ589307A (en) *	2008-04-29	2012-04-27	Pharnext	Compositions comprising baclogen or terbinafine for treating alzheimer disease and related disorders through a modulation of angiogenesis
MX2010011880A (es) *	2008-04-29	2011-05-25	Pharnext	Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
WO2009133128A1 (en) *	2008-04-29	2009-11-05	Pharnext	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2322163A1 (en) *	2009-11-03	2011-05-18	Pharnext	New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) *	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease

2009
- 2009-04-29 WO PCT/EP2009/055176 patent/WO2009133128A1/en not_active Ceased
- 2009-04-29 EA EA201071243A patent/EA024147B1/ru not_active IP Right Cessation
- 2009-04-29 JP JP2011506698A patent/JP5933258B2/ja not_active Expired - Fee Related
- 2009-04-29 EP EP19174818.5A patent/EP3560496A1/en not_active Withdrawn
- 2009-04-29 CN CN200980122702.4A patent/CN102065858B/zh not_active Expired - Fee Related
- 2009-04-29 CA CA2722295A patent/CA2722295C/en not_active Expired - Fee Related
- 2009-04-29 ES ES09738172T patent/ES2764480T3/es active Active
- 2009-04-29 KR KR1020107026052A patent/KR20110071050A/ko not_active Ceased
- 2009-04-29 BR BRPI0911874-8A patent/BRPI0911874A2/pt not_active Application Discontinuation
- 2009-04-29 EP EP09738172.7A patent/EP2285374B1/en active Active
- 2009-04-29 NZ NZ589304A patent/NZ589304A/en not_active IP Right Cessation
- 2009-04-29 AU AU2009242113A patent/AU2009242113B2/en not_active Ceased
- 2009-04-29 CN CN201410270079.XA patent/CN104127434B/zh not_active Expired - Fee Related
- 2009-04-29 MX MX2010011878A patent/MX2010011878A/es active IP Right Grant
2010
- 2010-10-28 IL IL208981A patent/IL208981B/en active IP Right Grant
- 2010-10-29 US US12/915,722 patent/US20110269764A1/en not_active Abandoned
- 2010-11-10 ZA ZA2010/08038A patent/ZA201008038B/en unknown
2014
- 2014-06-18 JP JP2014125058A patent/JP2014205697A/ja active Pending
2015
- 2015-11-30 US US14/954,388 patent/US10350195B2/en not_active Expired - Fee Related
2019
- 2019-02-07 IL IL264736A patent/IL264736B/en active IP Right Grant
- 2019-06-06 US US16/433,097 patent/US10874644B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2764480T3 (es)	2020-06-03
CA2722295A1 (en)	2009-11-05
US10350195B2 (en)	2019-07-16
CN102065858B (zh)	2014-07-02
CN104127434B (zh)	2017-10-13
CN102065858A (zh)	2011-05-18
ZA201008038B (en)	2011-08-31
CN104127434A (zh)	2014-11-05
JP2011518860A (ja)	2011-06-30
JP5933258B2 (ja)	2016-06-08
US20190298698A1 (en)	2019-10-03
EP2285374B1 (en)	2019-09-18
IL208981B (en)	2019-02-28
NZ589304A (en)	2012-03-30
AU2009242113A1 (en)	2009-11-05
JP2014205697A (ja)	2014-10-30
ES2764480T8 (es)	2020-07-24
US20110269764A1 (en)	2011-11-03
EA201071243A1 (ru)	2011-06-30
WO2009133128A1 (en)	2009-11-05
EP2285374A1 (en)	2011-02-23
CA2722295C (en)	2019-01-15
US10874644B2 (en)	2020-12-29
US20160136136A1 (en)	2016-05-19
KR20110071050A (ko)	2011-06-28
EP3560496A1 (en)	2019-10-30
AU2009242113B2 (en)	2014-09-11
MX2010011878A (es)	2011-04-11
IL208981A0 (en)	2011-01-31
EA024147B1 (ru)	2016-08-31
IL264736B (en)	2020-05-31

Legal Events

Date	Code	Title	Description
2018-05-29	B15I	Others concerning applications: loss of priority	Free format text: PERDA DA PRIORIDADE US61/048,582 DE 29/10/2010 POR NAO RESPOSTA DE EXIGENCIA. FOI SOLICITADO AO DEPOSITANTE A APRESENTACAO DE CESSAO DE PRIORIDADE CONTENDO O NUMERO DA PRIORIDADE REIVINDICADA NA FASE NACIONAL EM QUESTAO, CONFORME A RESOLUCAO 179 DE 21/02/2017. EM RESPOSTA O DEPOSITANTE APRESENTOU CESSAO DO PEDIDO AMERICANO 12/915,722 E DOCUMENTO COMPROVANDO QUE ESSE PEDIDO AMERICANO TAMBEM REIVINDICA A PRIORIDADE US61/048,582. DE ACORDO O A RESOLUCAO 179 DE 21/02/2017, O DOCUMENTO APRESENTADO NAO E SUFICIENTE PARA COMPROVAR A CESSAO DESSA PRIORIDADE.
2018-06-12	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-03	B25G	Requested change of headquarter approved	Owner name: PHARNEXT (FR)
2018-09-25	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001
2018-10-02	B12F	Other appeals [chapter 12.6 patent gazette]
2021-08-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-09-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-12-21	B09B	Patent application refused [chapter 9.2 patent gazette]
2022-03-08	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
IL264736B (en)	2020-05-31	Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
BRPI0818799A2 (pt)	2015-04-22	Composições para o tratamento da doença de parkinson
EP2151435A4 (en)	2011-09-14	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0911520A2 (pt)	2017-06-13	novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese.
PL2104682T3 (pl)	2017-03-31	Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
BRPI0911518A2 (pt)	2017-06-13	novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula
ZA201100034B (en)	2012-04-25	Pharmaceutical compositions for treatment of parkinson's disease
EP2382176A4 (en)	2015-09-09	USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL208926A0 (en)	2011-01-31	Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2091566A4 (en)	2011-07-06	COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
EP2152318A4 (en)	2011-12-07	COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
EP2282795A4 (en)	2016-01-06	TREATMENT OF RESPIRATORY DISEASES
WO2008002621A3 (en)	2008-02-21	Benzyl-substituted quinolone m1 receptor positive allosteric modulators
CR10245A (es)	2008-11-26	"nuevas combinaciones terapéuticas para el tratamiento de la depresión"
BRPI0720046A2 (pt)	2013-12-24	Composição de suplemento nutricional para tratamento de doenças oculares
PL2056842T3 (pl)	2013-03-29	Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
BR112012002265A2 (pt)	2016-06-14	composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
EP2306824A4 (en)	2013-10-23	IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
ZA200805761B (en)	2010-03-31	Pharmaceutical composition for the treatment of nail disease
FI20095600L (fi)	2009-06-09	Koostumus ihosairauksien hoitoa varten
EP2320939A4 (en)	2012-09-12	TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
BRPI0914454A2 (pt)	2015-10-27	"composição para o tratamento do tecido epitelial"
IL186022A0 (en)	2008-02-09	Dermatological compositions and salts for the treatment of dermatological diseases
EP2667896A4 (en)	2015-04-01	METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER
EP2117309A4 (en)	2011-04-06	BICYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE